🔴 LifeMD is trading 5% down today after Q2 revenue miss and reduced 2026 guidance

LifeMD is trading 5% down at $3.44 after its Q2 revenue miss and reduced 2026 guidance.

• The August 5, 2026, report showed revenue of $47.3 million, below the $49.15 million consensus, while adjusted EBITDA showed an approximately $3.5 million loss.
• Management reduced 2026 revenue guidance to $205.5 million–$212.5 million and adjusted EBITDA guidance to a loss of $6 million through breakeven.
• The decline appears company-specific: healthcare is higher, while broader indexes are only modestly lower; trading activity is elevated as the earnings reset continues.